



• Innovative Science

• Breakthrough Therapies

• Clinical Advances

# Center for Cancer Research Update

*Robert H. Wiltout, Ph.D., Director*


*Lee A. Helman, M.D., SD for Clinical Research*

*December 9, 2008*

**NCAB**




# CCR Is An Integral Part of NCI





## CCR Vision

**Integrate basic, translational, and clinical research to make cancer preventable, curable, or chronically manageable.**





## CCR Mission: Focused On The Patient

**To inform and empower the entire cancer research community by making breakthrough discoveries in basic and clinical cancer research and by developing them into novel therapeutic interventions for adults and children afflicted with cancer or infected with HIV.**





## CCR Seeks to Achieve Its Mission By:

---

- Performing **rigorous basic scientific research** to discover fundamental mechanisms of biology and cancer
- Translating these advances **rapidly from the laboratory to the clinic**
- Developing innovative technologies that enable **more accurate detection, diagnoses, and treatments**
- Pioneering novel interventions for **underserved patient populations**
- **Sharing expertise, scientific data and technologies** to broaden the impact of our work and enhance the overall productivity of the cancer research community
- Providing a unique environment to cultivate and **train future physician-scientists and biomedical researchers**



## CCR Scientific Presentations to the 148<sup>th</sup> Meeting of the NCAB

---

- **Dr. Natasha Caplen - Defining the Cancer Genome using RNAi Analysis and Screening**
- **Dr. Stephan Ambs - Application of Genomic Profiling to Identify Factors that contribute to Cancer Health Disparities**
- **Dr. Terry Van Dyke - Cancer Models: From Insight to Improved Care**
- **Dr. Marston Linehan – The Genetic Basis of Kidney Cancer: Opportunity for Targeted Approaches to Therapy**



# Center for Cancer Research Update – Closed Session

*Robert H. Wiltout, Ph.D.*  
*Director*

*December 9, 2008*  
*NCAB*



## Distinctive Qualities of CCR

- **Critical mass of basic and clinical scientists solving complex scientific problems**
- **Can quickly redeploy resources to address:**
  - (a) NCI mission goals-reduce the burden of cancer
  - (b) Urgent public need-response to AIDS epidemic
  - (c) New opportunities-decoding of the human genome
- **Access to NIH Clinical Center**





# Center for Cancer Research: Organization

## Center for Cancer Research

**Clinical Branches**

**Basic Laboratories**



- |   |   |
|---|---|
| <b>Cellular Oncology</b>                        | <b>Populations Genetics</b>                 |
| <b>Cell &amp; Cancer Biology</b>                | <b>Immune Cell Biology</b>                  |
| <b>Resistance Mechanisms</b>                    | <b>Macromolecular Crystallography</b>       |
| <b>Molecular Pharmacology</b>                   | <b>Cancer &amp; Inflammation</b>            |
| <b>Cancer Biology and Genetics</b>              | <b>Cell &amp; Developmental Signaling</b>   |
| <b>Cancer Prevention</b>                        | <b>Nanobiology</b>                          |
| <b>Genomic Diversity</b>                        | <b>Basic Research</b>                       |
| <b>Cell Biology</b>                             | <b>Molecular Biology</b>                    |
| <b>Molecular Pharmacology</b>                   | <b>Structural Biophysics</b>                |
| <b>Medicinal Chemistry</b>                      | <b>Protein Dynamics &amp; Signaling</b>     |
| <b>Molecular Targets Discovery</b>              | <b>Experimental Immunology</b>              |
| <b>Molecular Cell Biology</b>                   | <b>Comparative Carcinogenesis</b>           |
| <b>Cell Regulation &amp; Carcinogenesis</b>     | <b>Molecular Immunoregulation</b>           |
| <b>Experimental Carcinogenesis</b>              | <b>Cancer &amp; Development Biology</b>     |
| <b>Human Carcinogenesis</b>                     | <b>Mouse Cancer Genetics</b>                |
| <b>Retroviral Replication</b>                   | <b>HIV Drug Resistance</b>                  |
| <b>Mammary Biology &amp; Tumorigenesis</b>      | <b>Receptor Biology and Gene Expression</b> |
| <b>HIV Drug Resistance</b>                      | <b>Cellular Carcinogen &amp; Tumor Prom</b> |
| <b>Gene Regulation &amp; Chromosome Biology</b> | <b>Cellular &amp; Molecular Biology</b>     |
| <b>Biochemistry &amp; Molecular Biology</b>     |   |

# Center for Cancer Research: Organization



## Center for Cancer Research

### Clinical Branches



**Dermatology**  
**Medical Oncology**  
**Urologic Oncology**  
**Experimental Transplant. Immunol.**  
**Experimental Immunology**  
**Tumor Immunol. & Biology**  
**HIV & AIDS Malignancy**  
**Metabolism**  
**Biostatistics & Data Mgmt**

### Basic Laboratories

**Genetics**  
**Neuro-Oncology**  
**Pediatric Oncology**  
**Surgery**  
**Radiation Oncology**  
**Radiation Biology**  
**Pathology**  
**Molecular Imaging**  
**Vaccine**



# CCR Labs and Branches Are Woven Together Around Strategic Priorities

- **Understand the Cancer Process from Initiation to Metastasis**
- **Interrogate the Molecular Genetics of Cancer**
- **Improve Cancer Prevention, Early Detection, and Diagnostic Approaches**
- **Develop and Validate Novel Molecularly Targeted Interventions**
- **Harness the Immune System to Combat Cancer**
- **Discover and Develop Approaches to Combat HIV/AIDS and AIDS-associated Malignancies**





# Centers of Excellence serve as Focal Points for Bench to Bedside Translation

- **Centers of Excellence serve to support the IRPs dedication to long-term, high-risk, innovative basic, clinical, and epidemiologic research**

- Immunology - *Robert Wiltrout, Head*
- Chromosome Biology – *Gordon Hager, Head*
- HIV/AIDS and Cancer Virology - *Stuart LeGrice, Head*
- Molecular Oncology - *Giuseppe Giaccone, Pat Steeg, Head*
- Integrative Biology, *Snorri Thorgeirsson, Head*


### ***Program/Initiative***

- *Cancer and Inflammation – Giorgio Trinchieri, Head*




# Strategies for Programmatic Integration

## Translational Infrastructure Is Collaborative





# Research Emphasis Today



# Commercial Successes in Fighting Cancer and HIV



## ***Vaccines and Therapeutics***

***2-F-AraA - Fludara (April 18, 1991) Berlex  
Videx (October 9, 1991) Berlex Lab  
Hivid (June 19, 1992) BMS  
Paclitaxel (Dec. 29, 1992) BMS  
Trimetrexate – Neu Trexin (Dec. 17, 1993)  
Zenapax (Dec. 10, 1997) Hoffman La Roche  
Vitravene (Aug. 26, 1998) Isis Pharma  
Kepivance (Dec. 15, 2004) Amgen  
Zevalin (Feb. 19, 2002) IDEC Pharma  
Gardasil (June 8, 2006) Merck  
Prezista (June 23, 2006) Tibotec Pharma***

## ***Diagnostics***

***Serological Detection of Antibodies to HIV-1 (March 1, 1985)  
Serologic Detection of Antibodies to HTLV-1 (Nov. 29, 1988)  
DNA Probe for Breast Cancer Diagnosis (Dec. 11, 1998)  
Multi-replica Blotting Kit for Proteins***

## ***Instrumentation/Devices***

***Laser Capture Microdissection***



## Newly Tenured

---



Jairaj Acharya, MBBS, Ph.D.

---

Laboratory of Cell and  
Developmental Signaling

Phospholipid and sphingolipid signaling in Drosophila

---





## Newly Tenured

---




Javed Khan, M.D.

---

Pediatric Oncology Branch


Applying high throughput genomics and proteomics to characterize high risk pediatric malignancies, focusing on neuroblastoma.

# SV & BSC Recommendations






## FY08 Reallocations of Recovered Funds



**2.8 Million**



## Number of CCR PIs: 2000-2009



\* projected

◆ Projected 12 additional PIs in FY09

# Rebuilding the Principal Investigator Community – FY2008



## Senior Leadership

- Crystal Mackall, Chief, POB
- J. Carl Oberholtzer, Chief, LP
- Kevin Camphausen, Chief, ROB
- R. Andrew Byrd, Acting Director, Molecular Discovery Program
- Robert Yarchoan, Director for the NCI Office of HIV and AIDS Malignancies
- L. Michelle Bennett, Deputy Director CCR

## Newly Hired Tenure Tracks

- Itzhak Avital, SB
- Peter Kalab, LCMB
- Udai Kammula, SB
- Yamini Dalal, LRBGE
- Yinling Hu, LEI
- Jing Huang, LCBG
- Jung-Hyun Park, EIB
- Li Yang, LCBG
- Joseph Ziegelbauer, HAMB
- Ola Landgren, MOB
- Mitchell Ho, LMB
- Brian Lewis, MB
- Chris Buck, LOC
- Deb Citrin, ROB
- King Kwong, SB



## Open PI Positions (Nov 2008)

- **Mouse Cancer Genetics Program:** 2 Tenure Track or Tenured Positions
- **Laboratory of Human Carcinogenesis:** Tenure Track
- **Metabolism Branch:** 2 Tenure Track positions
- **Medical Oncology Branch:** Tenure Track in breast cancer
- **Laboratory of Biochemistry and Molecular Biology:** Tenure Track
- **Laboratory of Molecular Biology:** Tenure Track
- **Chronic Inflammation & Cancer:** Tenure Track
- **Neuro Oncology Branch:** Tenure Track



## Major Searches (Nov 2008)

---

- **Stem Cell Program**

- 29 applications received
- 15 top candidates reviewed by

**Search Committee**

- 6 top candidates interviewed

- **Chemical Biology Laboratory**

**Ad has been posted**

Overwhelmingly positive response from 24 well-qualified applicants, interviews are scheduled with 8 top candidates



○ Innovative Science

○ Breakthrough Therapies

○ Clinical Advances

# Center for Cancer Research Update – Closed Session

*Robert H. Wiltout, Ph.D.*  
*Director*

*December 9, 2008*  
*NCAB*





# The NCI Intramural Clinical Research Program

- **The NCI intramural clinical program *is not* a large volume, full-service cancer center**
- **The NCI intramural clinical program *is* the largest cancer-focused clinical research center (CRC) in the world, capable of performing patient-intensive clinical research focused on developing new approaches for prevention, diagnosis, and treatment of cancer.**
- **The NCI intramural clinical program is an important component of the nation's overall cancer program**